Camonsertib-PARP Inhibitor Combos May Meet Unmet Need in Advanced Solid Tumors
Combining camonsertib with PARP inhibitors may be an effective strategy for treating advanced solid tumors, a study suggests.
Combining camonsertib with PARP inhibitors may be an effective strategy for treating advanced solid tumors, a study suggests.
Increased risk of intracranial tumors, leukemia, and lymphoma by age 25 seen with exposure to four or more CT scans during childhood.
A recent study suggested that shopping data may help predict the risk of cancer. Now, researchers are exploring the implications of that finding.
The CARG and CRASH scoring systems were not predictive of severe adverse events in older patients receiving chemotherapy.
A research team developed a screening tool for frailty and comorbidities in patients with cancer aged 65 and older.
New research suggests that some cancer patients do not have their menstrual history documented and do not receive treatment for menstrual disturbances.
Cardiovascular disease (CVD), particularly atherosclerotic CVD, is associated with an increased risk of multiple cancers, research suggests.
Reduction seen in net cost savings from health care and societal perspectives; additional industry reformulation would increase policy impact.
A phase 2 study sought to determine the effectiveness and safety of psilocybin for the reduction of depression severity in patients with cancer.
History of hematologic, breast, lung, prostate cancer linked to increased risk for cardiovascular disease and mortality outcomes.